Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard M Stone

Showing results (1-10 of 420) with videos related to

Pageof 42
Sort By:
Blood|April 23, 2009
How I treat patients with myelodysplastic syndromesRichard M Stone
CA: a Cancer Journal for Clinicians|December 10, 2002
The difficult problem of acute myeloid leukemia in the older adultRichard M Stone
Blood|March 4, 2017
3 + 7 + FLT3 inhibitors: 1 + 1 ≠ 2Richard M Stone
Best Practice & Research. Clinical Haematology|March 6, 2007
Targeted agents in AML: much more to doRichard M Stone
Experimental Hematology|March 24, 2007
Novel therapeutic agents in acute myeloid leukemiaRichard M Stone
Best Practice & Research. Clinical Haematology|December 14, 2022
Consolidation chemotherapy in AML: Are we playing with a full deck of cards?Richard M Stone
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2013
Consolidation chemotherapy for adults with AML in first remission: is there a best choice?Richard M Stone
Blood|December 7, 2023
FLT(3)-ing about: the search for the best inhibitorRichard M Stone
Best Practice & Research. Clinical Haematology|December 7, 2010
New agents in post-remission therapyRichard M Stone
Best Practice & Research. Clinical Haematology|December 5, 2009
Prognostic factors in AML in relation to (ab)normal karyotypeRichard M Stone
Pageof 42

Showing results (1-10 of 420) with videos related to

Sort By:
Pageof 42
Blood|April 23, 2009
How I treat patients with myelodysplastic syndromesRichard M Stone
CA: a Cancer Journal for Clinicians|December 10, 2002
The difficult problem of acute myeloid leukemia in the older adultRichard M Stone
Blood|March 4, 2017
3 + 7 + FLT3 inhibitors: 1 + 1 ≠ 2Richard M Stone
Best Practice & Research. Clinical Haematology|March 6, 2007
Targeted agents in AML: much more to doRichard M Stone
Experimental Hematology|March 24, 2007
Novel therapeutic agents in acute myeloid leukemiaRichard M Stone
Best Practice & Research. Clinical Haematology|December 14, 2022
Consolidation chemotherapy in AML: Are we playing with a full deck of cards?Richard M Stone
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2013
Consolidation chemotherapy for adults with AML in first remission: is there a best choice?Richard M Stone
Blood|December 7, 2023
FLT(3)-ing about: the search for the best inhibitorRichard M Stone
Best Practice & Research. Clinical Haematology|December 7, 2010
New agents in post-remission therapyRichard M Stone
Best Practice & Research. Clinical Haematology|December 5, 2009
Prognostic factors in AML in relation to (ab)normal karyotypeRichard M Stone
Pageof 42